SAG (sensitive to apoptosis gene) or ROC2/RBX2 is the second family member of ROC1/RBX1, a component of SCF (Skp1, Cullin, F-box protein) and VCB (von HippelLindau (VHL), Cullin and Elongin B/C) E3 ubiquitin ligases. SAG protected cells from hypoxia-induced apoptosis when overexpressed. We report here that SAG was subjected to hypoxia induction at the levels of mRNA and protein. Hypoxia induction of SAG was largely HIF-1a dependent. A consensus HIF-1-binding site, GCGTG was identified in the first intron of the SAG gene. In response to hypoxia, HIF-1 bound to this site and transactivated SAG expression. SAG transactivation required both the intact binding site in cis and HIF-1a in trans. On the other hand, like its family member, ROC1, SAG promoted VHLmediated HIF-1a ubiquitination and degradation, which was significantly inhibited upon small interfering RNA silencing of SAG or ROC1. Furthermore, the endogenous HIF-1a at both basal and hypoxia-induced levels was significantly increased upon SAG silencing. Finally, SAG forms in vivo complex with Cul-5 and VHL under hypoxia condition. These results suggest an HIF-1-SAG feedback loop in response to hypoxia, as follows: hypoxia induces HIF-1 to transactivate SAG. Induced SAG then promotes HIF-1a ubiquitination and degradation. This feedback loop may serve as a cellular defensive mechanism to reduce potential cytotoxic effects of prolonged HIF-1 activation under hypoxia.
Introduction
Hypoxia is a condition in which tissue oxygen tension is reduced. Hypoxia in cancer tissues often results from uncontrolled proliferation of cancer cells that outgrow their blood supply leading to increased oxygen diffusion distances and inefficient and aberrant blood vessels with a poor blood flow (Harris, 2002) . Hypoxia is toxic to both cancer and normal cells, but cancer cells undergo genetic and adaptive changes that allow them to survive and even proliferate in a hypoxic environment. Cancer cells that adapt to hypoxia are more malignant, invasive and more resistant to radiation and chemotherapy (Harris, 2002 ).
An essential response to hypoxia in all metazoan species is the induction of HIF-1a. HIF-1a dimerizes with HIF-1b to form the active transcription factor, HIF-1 (Wang et al., 1995) . HIF-1 binds to hypoxia response elements, which contain the consensus HIF-1-binding site sequence 5
0 -(A/G)CGTG-3 0 and are located in proximity to many downstream target genes, leading to their transcriptional activation. The cellular levels of HIF-1a are tightly regulated via post-translational modification by prolyl hydroxylases and the VCB (von Hippel-Lindau (VHL), Cullin and Elongin B/C) E3 ubiquitin ligase complex (Maxwell et al., 1999; Ivan et al., 2001; Jaakkola et al., 2001) . In the presence of oxygen (normoxia), the prolyl hydroxylases are active and hydroxylate HIF-1a at proline residues 402 and 564. Hydroxylated HIF-1a is recognized by the VHL tumor suppressor protein, leading to ubiquitination by the VCB E3 ubiquitin ligase and subsequent proteasomal degradation. The asparaginyl hydroxylase FIH-1 hydroxylates HIF-1a at asparagine 803 and blocks its interaction with the transcriptional co-activators CBP and p300 (Lando et al., 2002) . Hypoxia inhibits both prolyl and asparaginyl hydroxylation and allows HIF-1a to accumulate and bind to CBP/ p300, leading to the transactivation of many downstream target genes (Pugh and Ratcliffe, 2003) .
Through differential display, we cloned SAG (sensitive to apoptosis gene), which encoded an evolutionarily conserved RING finger protein . Our further characterization revealed that SAG is a bi-functional protein with antioxidant activity when acting alone or with E3 ubiquitin ligase activity when complexed with other ligase components Swaroop et al., 1999) . It is well known that ROC1, a member of the same protein family as SAG, is a component of VCB E3 ubiquitin ligase, consisting of VHL tumor suppressor, Cullin 2, elongin B and elongin C (Ohta et al., 1999; Kamura et al., 1999b) , which promotes HIF-1a ubiquitination and subsequent degradation in a prolyl hydroxylase-dependent manner (Ivan et al., 2001) . VHL binds directly to HIF-1a and thus serves as a substrate recognition module, whereas ROC1 promotes cullin neddylation to facilitate the recruitment of an E2 ubiquitin conjugating enzyme (Kamura et al., 1999a) . However, whether SAG could replace ROC1 to form an SAG-VCB E3 ligase to promote HIF-1a degradation has not been previously established. We report here that SAG is induced at the transcription level by HIF-1 under hypoxia condition. Upon induction, SAG, like its family member, ROC1, promotes ubiquitination and degradation of HIF-1a. Thus, HIF-1-SAG constitutes a negative feedback loop in response to hypoxia.
Results
SAG induction by hypoxia occurs at both protein and mRNA levels SAG was originally cloned as a redox-regulated gene , and later found to be also inducible under hypoxic/ischemic conditions in mouse brain, rat heart and rat cardiomyocytes Chanalaris et al., 2003) . To extend this observation to human cancer cells, we determined whether SAG or ROC1 was subjected to induction by hypoxia. As shown in Figure 1a , expression of HIF-1a in DLD human colon cancer cells was significantly induced after 2 h of hypoxia and reached an induction peak at 8-16 h.
Induced levels decreased towards the basal levels at 24 h. SAG expression was low but detectable at the basal level, which started to increase upon hypoxia and reached a 4.5-fold induction peak at 8 h. The induced levels were then decreased gradually towards the basal level at 24 h. In contrast to HIF-1a and SAG, ROC1 was rather constitutively expressed at a relatively high level, and was not significantly induced by hypoxia. Thus, SAG is inducible under hypoxia with an induction pattern closely following the HIF-1a induction, whereas ROC1 is constitutively expressed and is not subject to hypoxia induction. Northern analysis revealed that hypoxia induction of SAG occurs at the mRNA level. The basal level of SAG was low, but detectable. Hypoxia caused a rapid increase of SAG mRNA with a peak induction at the 4-8 h. The induced levels gradually decreased towards the basal level at 24 h ( Figure 1b) . Thus, hypoxia-induced SAG induction occurs at both protein and mRNA levels with an mRNA induction preceding the protein induction.
SAG induction by hypoxia is HIF-1a dependent
We next determined whether SAG induction by hypoxia is HIF-1 dependent by using MEF cells from HIF-1a
and HIF-1a À/À mice (Feldser et al., 1999) . As shown in Figure 2a , HIF-1a was induced in HIF-1a þ / þ MEF cells starting 2 h post-hypoxia and reached a peak of 10-fold increase at 8 h. HIF-1a levels then decreased toward to the basal level by 24 h. As expected, HIF-1a was not detected in HIF-1a À/À MEF cells under normoxia nor hypoxia conditions. In parallel with HIF-1a induction, SAG expression was induced by hypoxia in HIF-1a þ / þ cells. SAG level started to increase at 2 h and reached the peak of 4.5-fold increase at 8 h and increased level was remained at 24 h. No significant SAG induction was 1.5 1.6 3.6 3.2 1.8 1.0 Figure 1 Hypoxia induction of SAG, but not ROC1 in human colon carcinoma DLD-1 cells. Subconfluent DLD1 cells were subjected to hypoxia for indicated periods of time up to 24 h. Cells were harvested, and subjected to immunoblotting (a) or northern analysis (b). The fold-induction relative to the untreated control was shown after densitometry quantification and b-actin or GAPDH normalization, respectively. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ROC1, regulator of cullins-1; SAG, sensitive to apoptosis gene. þ / þ and HIF-1a À/À mice were subjected to hypoxia for indicated periods time up to 24 h. Cells were harvested and subjected to western blotting (a) or northern analysis (b). The fold-induction relative to the untreated control was shown after densitometry quantification and b-actin or GAPDH normalization, respectively. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SAG, sensitive to apoptosis gene. seen in HIF-1a À/À MEF cells throughout hypoxia periods up to 24 h. Thus, SAG induction by hypoxia is mainly HIF-1a-dependent. Again, hypoxia-induced SAG expression occurred at the mRNA level as well. SAG mRNA was dramatically induced upon hypoxia in HIF-1a þ / þ cells and a moderate induction, if any, was seen in HIF-1a À/À cells (Figure 2b ).
A HIF-1 consensus binding site identified in the first intron of SAG gene to which HIF-1 binds upon hypoxia HIF-1a-dependent induction of SAG occurring at both mRNA and protein levels strongly suggested that SAG could be a novel HIF-1 target gene. We searched for consensus HIF-1-binding site, A/GCGTG (Wang et al., 1995) within a region of 5 kb upstream from the translational initiation site and a 5.0 kb intron-1 region of the human SAG genomic sequence (accession no. AC112771), and identified one perfected match, 5 0 -GCGTG-3 0 , at the nucleotides 625-629 downstream from the exon-1/ intron-1 boundary. Figure 3a listed this 695 bp intron-1 sequence with HIF-1-binding site boxed and primers for ChIP (chromatin immunoprecipitation) amplification (see below) underlined. We determined whether HIF-1 would bind to this site in vivo in response to hypoxia. As shown in Figure 3b ChIP analysis: DLD-1 cells were grown under normoxia or hypoxia for 14.5 h, followed by ChIP analysis. The DNA lysates were used directly as PCR templates (input), or subjected to immunoprecipitation without antibody added (No-Ab), or with IgG, or HIF-1a antibody. The DNA precipitates were subjected to PCR amplification using primer set for SAG intron 1 (upper panel) or VEGF promoter (bottom panel), as positive control. (c) HIF-1-binding site dependent SAG transactivation under hypoxia. DLD-1 cells were plated in 96-well plates and transiently co-transfected with luciferase reporters driven by hSAG-I-0.6wt (SAG-WT), hSAG-I-0.6-M (SAG-M) or VEGF-Luc positive control or pGL-3 negative control, respectively, along with Renilla-luc reporter. Thirty-six hours post-transfection, cells were subjected to either normoxia or hypoxia for 8 h, followed by luciferase activity assay. (d) HIF-1a-dependent SAG transactivation under hypoxia.
HIF-1a
þ / þ and HIF-1a À/À MEF cells were plated in 96-well plate and transiently transfected with above four constructs, respectively, along with Renilla-luc reporter. Thirty-six hours post-transfection, cells were subjected to hypoxia for 8 h, followed by luciferase activity assay. Luciferase activity from three independent transfections, each run in triplicate was presented as fold activation after normalization of transfection efficiency by arbitrarily setting the value of pGL-3 as 1. ChIP, chromatin immunoprecipitation; SAG, sensitive to apoptosis gene.
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M Tan et al the exon-1/intron-1 boundary, respectively, providing structural basis for HIF-1-dependent induction of mouse SAG seen in MEF cells (Figure 2 ). Thus, SAG induction by HIF-1 is evolutionarily conserved with HIF-1 cis element identified in the first intron of both human and mouse origins.
HIF-1-binding site-and HIF-1a-dependent transactivation of SAG in response to hypoxia Two luciferase reporters driven by 631 bp SAG intron-1 fragment with a wild-type HIF-1-binding site (hSAG-I-0.6-wt) or a mutant HIF-1 site (hSAG-I-0.6-M, GCGTG-GAAAG) were generated and tested under normoxia and hypoxia conditions. As shown in Figure 3c , under normoxia condition, a minimal of two-to fourfold higher luciferase activity than that of the empty vector was detected in hSAG-I-0.6-wt or hSAG-I-0.6-M, respectively. The VEGF-Luc reporter also gave rise to a twofold increase of luciferase activity above the empty vector control. However, under hypoxia condition, an eightfold induction of luciferase activity in hSAG-I-0.6-wt construct was observed. This induction was dependent of the HIF-1-binding site, since it was completely abolished if the site was mutated, as evident by a lack of hypoxia-induced change of luciferase activity in hSAG-I-0.6-M construct. The VEGF-luc-positive control (Forsythe et al., 1996) gave rise to a 13-fold induction of luciferase activity. These results strongly suggest that hypoxia-induced SAG transactivation is largely dependent of intact HIF-1-binding site.
To further confirm an HIF-1a dependent SAG transactivation, we again used MEF cells from HIF-1a
and HIF-1a À/À mice. Compared to the vector control, luciferase activity of hSAG-I-0.6-wt construct under hypoxic condition was 8.5-fold higher in HIF-1a þ / þ , but less than 1.5-fold higher in HIF-1a À/À cells. Thus, a sixfold difference between two types of cells was observed (Figure 3d) . A 14-fold difference was found in luciferase reporter driven by VEGF promoter. In contrast, when hSAG-I-0.6-M construct was used, a less than 1.5-fold increase in luciferase activity was seen between two lines (Figure 3d ). This minor increase could be due to a second HIF-1-binding site, located at nucleotides 157-161 of this intron sequence, but in an opposite orientation (5 0 -CACGC-3 0 ). It is noteworthy that this site failed to respond to hypoxia when tested in DLD-1 cells using hSAG-I-0.6-M (Figure 3c ). In summary, induction of SAG expression under hypoxia is largely attributable to transcriptional activation by HIF-1, which requires intact HIF-1-binding site in cis and HIF-1a in trans.
SAG involvement in VHL-mediated HIF-1a ubiquitination and degradation Since SAG is a second member of ROC1 RING family and is induced under hypoxic conditions, we hypothesized that SAG, like ROC1, can promote VHLmediated ubiquitination and degradation of HIF-1a. As shown in Figure 4a , a relatively high level of HIF-1a was detected in 293 cells after transient transfection of HIF-1a (lane 1). Co-transfection of HIF-1a with VHL promoted HIF-1a degradation, as evidenced by a decrease in HIF-1a level (lanes 2 vs 1). However, cotransfection of a mutant VHL-Y98H, which is unable to bind to HIF-1a (Corn et al., 2003) , failed to reduce, but increased HIF-1a level, suggesting a dominant-negative effect of this mutant (lanes 3 vs 1) . On the other hand, like VHL, but to a lesser extent, co-transfection of HIF-1a with ROC1 or SAG also decreased the levels of HIF-1a (lanes 4 and 5 vs 1). The combination of VHL with ROC1 (lane 6) or with SAG (lane 7) further increased HIF-1a degradation as evidenced by an even lower level of HIF-1a than VHL transfection alone (lanes 6 and 7 vs 2). Expression of VHL, VHL mutant, ROC1 and SAG were readily detectable (middle panel). The results clearly showed that SAG is as effective as ROC1 in promoting VHL-induced HIF-1a degradation.
We next used an in vivo ubiquitination assay to measure the role of SAG in VHL-mediated HIF-1a ubiquitination. As shown in Figure 4b (top panel) His-Ub-tagged HIF-1a (ubiquitinated HIF-1a), which appeared as slower migrating smeared bands, was readily detectable when HIF-1a was co-transfected with VHL (lanes 4 vs 3). This VHL-mediated HIF-1a ubiquitination was further enhanced by the co-transfection of SAG (lane 5), but inhibited by the co-transfection of SAG small interfering RNA (siRNA) (psiSAG, lane 7), not Control siRNA (psiCont, lane 6). Expression of HIF-1a (second panel), VHL (third panel) and SAG (fourth panel) were readily detectable. The results demonstrated that SAG promotes VHL-induced HIF-1a ubiquitination.
siRNA silencing of SAG inhibited VHL-induced HIF-1a degradation and promoted HIF-1a accumulation upon hypoxia We next determined the effect of siRNA silencing of SAG or ROC1 on VHL-mediated HIF-1a degradation. As shown in Figure 5a (top panel) a relatively high level of HIF-1a was detected in 293 cells after transient transfection of HIF-1a (lane 1). VHL promoted HIF-1a degradation dramatically when it was co-transfected with control siRNA, psiCont (lane 3). However, the VHLmediated HIF-1a degradation was completely blocked, when SAG or ROC1 was silenced by psiSAG or psiROC1, respectively (lanes 5 and 7). The observation that MG132, a proteasome inhibitor, increased the HIF1a levels even in the absence of exogenous VHL (lanes 2 vs 1) suggested that endogenous SAG/ROC-VHL E3 ligase played a role in promoting degradation of exogenously expressed HIF-1a. Furthermore, MG132 completely blocked HIF-1a degradation induced by exogenously expressed SAG/ROC1-VHL E3 ubiquitin ligases (lanes 4, 6 and 8). Taken together, both overexpression and siRNA silencing experiments indicate that like ROC1, SAG is capable of promoting VHL-mediated ubiquitination and degradation of HIF-1a.
Furthermore, we determined whether siRNA silencing of SAG would affect endogenous levels of HIF-1a under normoxia and hypoxia conditions. As shown in Figure 5b , in psiCont-transfected H1299 cells, the basal levels of HIF-1a and SAG were low, but detectable (lane 1). Hypoxia significantly induced both HIF-1a and SAG upon hypoxia up to 24 h (lanes 3, 5, 7 and 9). However, in psiSAG-transfected cells, the basal SAG level was completely blocked (lane 2), whereas hypoxiainduced SAG was largely blocked as well (lanes 4, 6, 8 and 10). SAG silencing resulted in a significant increase of the endogenous HIF-1a at both the basal (lane 2) and hypoxia-induced levels at each time point tested up to 24 h (lanes 4, 6, 8 and 10). Neither siRNA silencing of SAG nor hypoxia exposure had any effect on ROC1 expression (panel 3). Thus, endogenous SAG is involved in HIF-1a turnover under normoxia as well as hypoxia conditions and its silencing promotes HIF-1a accumulation by blocking its degradation under both conditions. SAG forms a complex with VHL and Cul-5, but not Cul-2 under hypoxia condition It has been recently shown that VHL interacted with Cul2-RBX1/ROC1, whereas SOCS-box protein associated with Cul5-RBX2/SAG under normoxia conditions (Kamura et al., 2004) . We extended this observation by determining whether SAG could form a complex with Cul-5 but not Cul-2 in HeLa cells under hypoxia condition. A HeLa cell clone (HSW16) that stably expresses hemagglutinin (HA)-tagged-SAG at the level of two-to threefold higher than that of endogenous SAG was used, along with vector control line HSC1 (Figure 6a , panel 4). Since SAG is subjected to hypoxia induction up to fourfold, we feel that this increased level of SAG is within the range of being physiologically relevant. Immunoprecipitation (IP) with HA-antibody pulled down HA-SAG in HSW16, but not in HSC1 cells, as expected. Co-IPed with SAG was endogenous Cul-5, but not endogenous Cul-2 (Figure 6a , top three panels), although both Cul-5 and Cul-2 were expressed in HeLa cells (panels 5 and 6). This result confirmed and extended the observation made by Kamura et al. (2004) to indicate that SAG binds to endogenous Cul-5, but not Cul-2 in vivo under both normoxia and hypoxia conditions. Previous work also showed that ROC1, but not SAG/ ROC2 can be detected in VHL immunoprecipitates under normoxia conditions (Kamura et al., 2004) . We went on to determine whether SAG binds to VHL only under hypoxia. We included MG132 to facilitate the potential interaction of SAG-VHL as used to detect Rbx1-VHL binding (Kamura et al., 2004) . Indeed, IP with HAantibody pulled down HA-SAG in HSW16 cells. The VHL was detected in SAG-immunoprecipitates, only under the condition of hypoxia-proteasome inhibitor, MG132 (Figure 6b, lane 8) , although the similar levels of VHL were expressed among all samples. Finally, a reciprocal immunoprecipitation with VHL antibody was performed to determine the relative amount of endogenous Cul2/ROC1 and Cul5/SAG in the VHL immunoprecipitates. As shown in Figure 6c , VHL can be readily pulled down by VHL antibody, along with ROC1 and In vivo ubiquitination assay. H1299 cells were transiently transfected with a variety of plasmid constructs, as indicated. Thirty-eight hours post-transfection, one portion of cells was lysated and His-Ub-tagged proteins were purified through nickel beads. His-Ub-HIF-1a was detected by western blotting using anti-HIF-1a antibody. The other portion of cells was subjected to western blotting (panels 2-4). HA, hemagglutinin; SAG, sensitive to apoptosis gene.
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Cul-2 (lanes 1-8). Weak SAG and Cul-5 can be detected again only under combination of hypoxia and proteasome inhibitor, MG132 (lane 8). Thus, although VHL mainly binds to Cul-2/ROC1, it is also associated with SAG/Cul-5 in vivo, particularly under hypoxia condition to facilitate HIF-1a degradation.
Discussion
We have previously shown that SAG is a stress responsive gene that is induced by redox agents and ischemia/reperfusion in multiple cell lines and normal tissues and acts as a cellular defense mechanism to protect cells or tissues from apoptosis induced by these stresses Yang et al., 2001; Chanalaris et al., 2003) . However, the molecular mechanism by which SAG is regulated by ischemia-induced hypoxia is unclear. We report here that hypoxia inducible SAG is subject to transcriptional activation by HIF-1, thus SAG is a novel HIF-1 target. Four lines of evidence presented in this study support this conclusion.
(1) Hypoxia-mediated SAG induction occurs at both mRNA and protein levels; (2) SAG induction follows HIF-1a induction under hypoxia; (3) HIF-1 binding to a HIF-1 consensus-binding site found in the first intron of the SAG gene in response to hypoxia and HIF-1-mediated SAG transactivation is dependent upon this site in cis and (4) SAG induction by hypoxia is dependent on HIF-1a in trans. Due to the nature of SAG function as a cellular survival protein, SAG joins other HIF-1-regulated genes, such as those encoding IGF2 and IGF-BPs (Tazuke et al., 1998; Feldser et al., 1999) that activate survival pathways to protect cell death as a cellular protective/adaptive response to hypoxia. As a cell survival protein, SAG appears to have dual functions. When acting alone, SAG functions as an antioxidant to scavenge reactive oxygen species and inhibit reactive oxygen species-induced DNA damage, lipid peroxidation and mitochondria injury Swaroop et al., 1999; Kim et al., 2003) . When complexed with other E3 ubiquitin ligase components, SAG promotes ubiquitination and degradation of a number of protein substrates (Sun et al., 2001 ). Here we showed that SAG, like its family member ROC1, is capable of regulating HIF-1a level. When overexpressed, it promotes and when silenced, it blocks VHL-mediated HIF-1a ubiquitination and degradation. The SAG involvement in degradation of endogenous HIF-1a induced by hypoxia was further confirmed through SAG siRNA silencing experiment. It has been well established previously; the ROC1 is the RING component of VCB E3 ligase that is involved in the ubiquitination and degradation of HIF-1a in vitro (Kamura et al., 1999b (Kamura et al., , 2000 . However, this is the first report that SAG also has such an activity in transfected cells with the activity equal to that of ROC1.
It has been recently shown that under normoxia condition, VHL interacted with endogenous Elongin B, Elongin C, Cul-2 and ROC1/Rbx1, but not with Cul-5 or SAG/ROC2, whereas SOCS3 interacted with endogenous Elongin B, Enogin C, Cul-5 and SAG, but not with Cul-2 or ROC1 (Kamura et al., 2004) . Our study, on the other hand, revealed an in vivo formation of VHL-SAG-Cul-5, but not VHL-SAG-Cul-2, only under hypoxia condition in combination with MG132 treatment. The requirement of MG132, a proteasome inhibitor, known to stabilize the proteins by inhibiting their degradation, suggests that the VHL-SAG-Cul-5 binding, if any, is quite weak and not detectable under normoxia and that the detection of such binding requires hypoxia-mediated induction and MG132-mediated accumulation of SAG, VHL and/or Cul-5. It appears that VHL, SAG and Cul-5, along with other component(s), are likely to form an active E3 ubiquitin ligase, particularly under hypoxia, for HIF-1a degrada- Cell lysates were then prepared and subjected to western blotting analysis using antibodies as indicated. (b) Accumulation of endogenous HIF-1a. H1299 cells were transiently transfected with psiSAG or psiCont, respectively. Twenty-four hours post-transfection, cells were exposed to hypoxia for a variety of time periods up to 24 h, followed by western blotting. DMSO, dimethyl sulfoxide; SAG, sensitive to apoptosis gene.
SAG and HIF-1: target and substrate M Tan et al tion to keep HIF-1a levels in check. Future study is directed to identify these remaining components of VHL-SAG-Cul-5 ligase.
Our study strongly suggests an auto-feedback loop between HIF-1 and SAG, in analogy to p53-Mdm2 auto-feedback regulation (Wu et al., 1993) . Under hypoxic conditions, HIF-1a is induced. Induced HIF-1a complexes with HIF-1b to constitute an active transcription factor, HIF-1 (Wang et al., 1995) . Activated HIF-1 then transactivates the SAG gene. Induced SAG protein then most likely recruits other components, including VHL and Cul-5, of E3 ubiquitin ligase to promote ubiquitination and degradation of HIF-1a, thus downregulating HIF-1 activity. Although both SAG and ROC1 have similar E3 ligase activity towards HIF-1a, hypoxia-inducible SAG differs from constitutively expressed ROC1 as a cellular response to stress such as hypoxia. Given the fact that HIF-1 stabilizes p53, which in turn transactivates a list of proapoptotic genes to induce apoptosis (Sun, 2006) , and that SAG inhibits hypoxia-induced apoptosis in mouse brain and rat heart Chanalaris et al., 2003) , it is very likely that one ligase-associated mechanism by which SAG protects tissues or cells from hypoxia is through the ubiquitination and degradation of HIF-1a. Thus, the HIF1-SAG auto-feedback loop may serve as a cellular defensive mechanism to reduce potential cyto-toxic effect induced by a prolonged HIF-1 activation.
Materials and methods
Cell culture and hypoxia exposure Human DLD-1, H1299, HeLa and 293 cells were cultured in Dulbecco's modified Eagles's medium containing 10% fetal bovine serum. Mouse MEF cell lines from HIF-1a
and HIF-1a À/À mice (Feldser et al., 1999) were cultured in Dulbecco's modified Eagles's medium containing 15% fetal bovine serum and 1 Â non-essential amino acids. For hypoxia exposure, cells were placed for a variety of time periods up to 24 h in a hypoxia chamber (Biospherix, Redfield, NY, USA), supplied with 95% N 2 and 5% CO 2 .
Northern, western blotting and immunoprecipitation Assays were performed as described (Gu et al., 2007) after cells were exposed to hypoxia for up to 24 h. The antibodies used are HIF-1a, Cul-5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), HA-tag (Roche, Pleasanton, CA, USA) or FLAGtag and b-actin (Sigma, St Louis, MO, USA), Cul-2 (BD Biosciences, San Jose, CA, USA), VHL (BD Biosciences) and SAG and ROC1.
Intron-1 cloning, luciferase reporter construction and luciferase activity assay A 631 bp DNA fragment immediately downstream of exon/ intron 1 boundary was amplified by PCR. The primers used are SAG-I03 (5 0 -CGGGGTACCGTAAGCGCTGCACGC G AGTC-3 0 ) and SAG-I04 (5 0 -CCCAAGCTTCCACGCTAGT GCTATCTGA-3 0 ) with HIF-1-binding site underlined. The primers SAG-I03 and SAG-I04 M (5 0 -CCCAAGCTTCCTT TCTAG TGCTATCTGA-3 0 ) were used to generate a 631 bp DNA fragment with HIF-1-binding site mutated (underlined nucleotides). The fragments were subcloned and luciferase activity measured without or with hypoxia exposure as described (Gu et al., 2007) .
Chromatin immunoprecipitation assay
The assay was performed as described (Gu et al., 2007) Formation of Cul-5-SAG-VHL complex under hypoxia condition. (a) SAG binds to Cul5, but not Cul-2: HeLa SAG stable clone (HSW16) and the vector control clone (HSC1) was subjected to hypoxia for 24 h, followed by immunoprecipitation by HA-antibody and western blotting or direct western blotting. (b and c) SAG binds to VHL. HSW16 and HSC1 cells were left untreated (lanes 1 and 2), or treated with MG132 alone (lanes 3 and 4), hypoxia alone (lanes 5 and 6) or in combination of hypoxia and MG132 (lanes 7-9). The cell lysates were prepared and subjected to immunoprecipitation using HA-antibody (b) or VHL-antibody (c) or preimmuno-IgG, followed by western blotting, or directly subjected to western blotting. HA, hemagglutinin; SAG, sensitive to apoptosis gene.
SAG and HIF-1: target and substrate M Tan et al AGTTTGTGGA GCTGA-3 0 ) to generate a 119 bp fragment. The IP antibody used was HIF-1a or normal IgG as negative control. One-tenth original DNA lysates was used as input control.
In vivo ubiquitination assay and siRNA silencing Assays were performed as described (Gu et al., 2007) .
